Welcome to our dedicated page for Xenon Pharmaceut news (Ticker: XENE), a resource for investors and traders seeking the latest updates and insights on Xenon Pharmaceut stock.
Xenon Pharmaceuticals Inc. reports news on its neuroscience-focused biopharmaceutical pipeline, including drug discovery, clinical development and commercialization plans for neurological and psychiatric disorders. The company’s lead molecule, azetukalner, is a KV7 potassium channel opener in Phase 3 clinical development for epilepsy, major depressive disorder and bipolar depression.
Recurring updates include azetukalner clinical data in focal onset seizures, presentations at medical and investor conferences, financial results, business updates, public offerings, inducement equity grants and early-stage potassium and sodium channel programs, including KV7 and NaV1.7 candidates being developed for pain.
Xenon Pharmaceuticals (Nasdaq: XENE) will announce topline results from the Phase 3 X-TOLE2 study of azetukalner in focal onset seizures on Monday, March 9, 2026. A live webcast and replay will be available via the company's Investors website; conference call details are provided.
Conference call: 8:00 am ET (5:00 am PT) on March 9, 2026; dial-in and webcast registration information available.
Xenon Pharmaceuticals (Nasdaq: XENE) reported Q4 and full-year 2025 results and a business update highlighting imminent clinical and cash milestones. X-TOLE2 Phase 3 topline data in focal onset seizures are expected in the first half of March 2026, with an anticipated NDA submission in H2 2026. Pro forma cash of $716.0M (including Q1 2026 ATM proceeds) supports operations into the second half of 2027. Multiple Phase 3 azetukalner studies continue to enroll; X-NOVA2 MDD topline data expected H1 2027. Early-stage Phase 1 data for XEN1701 and XEN1120 expected in 2026.
Xenon Pharmaceuticals (Nasdaq: XENE) announced inducement equity grants to ten new non-officer employees totaling 42,300 share options, approved by the Compensation Committee with an effective date of January 15, 2026 under Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $40.74 per share (equal to the closing price on the grant date), vest over four years with 25% vesting after one year and the remainder vesting monthly (1/36th) thereafter, and each option has a 10-year term and is subject to the company’s 2025 Inducement Equity Incentive Plan and option agreements.
Xenon Pharmaceuticals (Nasdaq: XENE) outlined near-term clinical and regulatory milestones at the 2026 J.P. Morgan Healthcare Conference. Key timelines include X-TOLE2 topline data in March 2026 for azetukalner in focal onset seizures (380 patients randomized) and an anticipated NDA submission in H2 2026. Five additional placebo-controlled Phase 3 azetukalner studies remain active across epilepsy and neuropsychiatry, with X-NOVA2 topline data expected H1 2027 for major depressive disorder. Phase 1 SAD/MAD data for pain candidates XEN1701 (NaV1.7) and XEN1120 (KV7) are expected in 2026 to support Phase 2 proof-of-concept studies. The company also reported long-term OLE results showing sustained seizure reductions and detailed plans to support regulatory filings in multiple regions.
Xenon Pharmaceuticals (Nasdaq: XENE) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 12, 2026. The company presentation is scheduled for 9:00–9:40am PT (12:00–12:40pm ET) and will be delivered by Ian Mortimer, President and CEO. A live audio webcast will be available on Xenon’s investor website and posted for replay after the event. Dates and times are subject to change.
Program highlights: Xenon described its lead molecule azetukalner as a Kv7 potassium channel opener in Phase 3 for epilepsy, major depressive disorder and bipolar depression, and noted early-stage Kv7 and NaV1.7 programs in Phase 1 for pain.
Xenon (Nasdaq: XENE) presented interim 48-month open-label extension (X-TOLE OLE) data for azetukalner at AES 2025 showing durable seizure reductions and intervals of sustained seizure freedom. Among participants treated ≥48 months (n=131) the monthly median percent change in focal-onset seizure frequency improved from a 69.8% reduction at OLE month 1 to a 90.9% reduction at OLE month 48. Subgroup results showed a 100% monthly reduction for those on 1–2 ASMs (n=60) and 81.8% for those on 3 ASMs (n=69). Seizure freedom for ≥12, ≥24, ≥36, and ≥48 months was attained by 38.2%, 25.2%, 19.8%, and 10.7%, respectively. Analyses found many patients who experienced breakthrough seizures regained extended seizure-free epochs with continued treatment. Long-term safety was reported as comparable to the double-blind period. Additional real-world and preclinical Dravet data were also presented.
Xenon Pharmaceuticals (Nasdaq: XENE) announced equity inducement grants on December 4, 2025 to five new non-officer employees totaling 39,250 share options. The options carry an exercise price of $44.61, equal to Xenon’s closing share price on the grant date, vest over four years (25% after one year, then monthly vesting), and have a 10-year term. Grants were approved by the Compensation Committee and issued under Nasdaq Listing Rule 5635(c)(4) and the company’s Amended and Restated 2025 Inducement Equity Incentive Plan.
Terms are subject to each option agreement and continued service; the company highlighted its lead asset azetukalner in Phase 3 and earlier-stage ion channel programs.
Xenon (Nasdaq: XENE) will host an investor webinar on December 10, 2025, 10:00 AM ET to review data presented at the American Epilepsy Society Annual Meeting (AES 2025).
The webinar covers new long-term results from the ongoing X-TOLE open-label extension of azetukalner in focal onset seizures, real-world data on depression and titration burden in epilepsy, and an update on preparations for commercialization of azetukalner. A live webcast and replay will be available on the company Investors site.
Xenon Pharmaceuticals (Nasdaq: XENE) will present seven posters at AES 2025 (Dec 5–9, 2025) highlighting long-term clinical and preclinical epilepsy data.
Key highlights include a ≥48‑month interim analysis from the ongoing X-TOLE open‑label extension of azetukalner in focal epilepsy, characterization of long-term seizure‑freedom epochs, patient‑reported depression and titration burden studies, and preclinical NaV1.1 data in Dravet mice reporting suppression of spontaneous seizures, prevention of SUDEP, and increased long‑term potentiation.
Sessions, symposium and a scientific exhibit will be held Dec 6–8 in Atlanta; posters available after live presentations.
Xenon Pharmaceuticals (Nasdaq: XENE) will present at two investor conferences in November 2025: the Stifel 2025 Healthcare Conference on Thursday, November 13, 2025 at 3:20 PM ET and the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025 at 11:30 AM GMT / 6:30 AM ET. Webcasts are mentioned and will be posted for replay when available. Dates and times are subject to change.
The release reiterates Xenon’s focus on neuroscience drug discovery and development, notes lead molecule azetukalner is in Phase 3 for epilepsy, MDD and BPD, and references Phase 1 programs for Nav1.7 and Kv7 targeting pain. Investor materials and webcast links will be available on Xenon’s Investors webpage.